JSR-LIFE-SCIENCES
JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to purchase Crown Bioscience International (TPEx: ticker 6554) at 12 Billion New Taiwan Dollar, a global drug discovery and development services company providing translational platforms to advanced oncology, inflammation, cardiovascular and metabolic disease research. This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include industry-leading contract research and development capabilities, and ability to develop impactful solutions for pharma.
As a premier contract research organization (CRO), CrownBio has deep industry relationships and a global footprint that will complement JSR’s already global presence. Upon completion of the acquisition, JSR Life Sciences’ will enjoy a full suite of integrated capabilities that extend from pure research, to drug discovery, diagnostics development, cell line development and process development, through to GMP manufacturing.
“We are positioning to be the clear choice for innovation-driven strategic partnerships,” said Eric R. Johnson, President of JSR’s Life Sciences Division. “CrownBio, and its science-rich approach, is an ideal fit to support that goal. We’re bringing together innovative competencies that will lead to better solutions for pharma and improve their ability to take therapeutics to the market.”
As focus on personalized medicine continues to increase, CROs are turning into scientific leaders. Translational platforms, bioinformatics and modeling capabilities, like CrownBio’s patient-derived xenograft (PDX) models, are becoming fundamentally important to the development and commercialization of diagnostics and therapeutics. JSR’s forecast, based on consultation with CrownBio’s management team, is for the company to realize Revenue and EBITDA margin of 90 and 20 M USD respectively in 2018, with the understanding that such projected financial information may vary from actual results.
JSR has had extensive M&A activity in recent years. The 2015 majority interest acquisitions of contract development and manufacturing organization KBI Biopharma, Inc. and MBL Corporation, and the 2017 acquisition of mammalian cell line development pioneer Selexis SA, combine to be a strong technology engine for innovation.
JSR envisions that CrownBio’s development capabilities will enhance the contribution of JKiC, the company’s Japan-based industry-academia-medicine collaboration hub, by providing the tools and expertise to translate leading-edge research into tomorrow’s medicines.
About Crown Bioscience
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
About JSR Corporation
JSR Corporation is a multinational company with research-oriented organization that pursues close collaborations with leading innovators in a number of industries that are a key to the present and future welfare of human society: life sciences, synthetic rubbers, electronic materials, display and optical materials. JSR Corporation conducts its global life sciences business through its JSR Life Sciences Business Division. JSR Life Sciences provides specialized materials, products and services to the biotech industry both directly and through its subsidiaries Medical & Biological Laboratories Co. Ltd, KBI Biopharma, Inc. and Selexis SA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171220005165/en/
Contact:
JSR Life Sciences
Missy Bindseil, 1-830-237-9527
mbindseil@jsrlifesciences.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street and ServiceNow Partner with Apsen Farmacêutica to Deliver a Next-Generation Vision of Enterprise-Wide Workflow Automation7.5.2025 18:55:00 CEST | Press release
Pharmaceutical manufacturer layers ServiceNow over its existing SAP ECC 6 ERP platform, enables intelligent workflow and automation for immediate business impact and avoids low ROI spend on expensive, risky vendor-mandated migration to SAP S/4HANA Knowledge 2025 —Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today at ServiceNow’s annual customer and partner event, Knowledge 2025, announced that Apsen Farmacêutica, a Brazilian pharmaceutical manufacturer, has partnered with Rimini Street and ServiceNow to implement a next-generation vision of enterprise-wide workflow automation. This new vision will enable autonomy across the company to help respond faster to market changes, reduce information silos and improve operational efficiency. This press release features multimedia. View the full release here: https://www.busine
Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials7.5.2025 18:07:00 CEST | Press release
Study conducted by VirTus Respiratory Research demonstrated that vapendavir has potent antiviral activity and improves symptoms in participants with COPD infected with rhinovirus VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507489716/en/ Professor Sebastian Johnston https://www.prnewswire.com/news-releases/altesa-biosciences-details-positive-topline-vapendavir-results-from-phase-2-placebo-controlled-rhinovirus-challenge-study-in-copd-patients-302448650.html Rhinovirus infection is the cause of at least half of the acute respiratory deteriorat
FlightSafety International Announces Major Expansion at Farnborough Airport7.5.2025 17:56:00 CEST | Press release
FlightSafety International (FSI), a global leader in aviation training, is pleased to announce the expansion of its facilities at Farnborough Airport, the home of British aviation and Europe’s leading airport for premium air travel connectivity, highlighting its commitment to enhancing aviation safety and training excellence in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506583636/en/ Rendering: arriving at FlightSafety International The new FSI centre is expected to open in the second quarter of 2027. Lease terms have been finalised and the planning application was submitted in January. Construction is scheduled to start in late 2025 and finish by early 2027. FSI has operated a training centre at Farnborough Airport since 2004. The new facilities will boost training capacity by 40-50%, enabling more aviation professionals access to FSI's world-class training programmes. The current facility is 4,680 square met
Verimatrix Positioned as a Leader and Ace Performer in the 2025 SPARK MatrixTM for In-App Protection by QKS Group7.5.2025 17:45:00 CEST | Press release
The QKS Group SPARK Matrix™ provides competitive analysis and ranking of the leading In-App Protection vendors.Verimatrix is recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™.Verimatrix has also been named an Ace Performer – a recognition given to vendors that demonstrate revenue growth potential, partnership strategy, and customer acquisition – all evaluated over the last one-year period or since the previous SPARK Matrix™ assessment. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507970501/en/ Verimatrix positioned as a Leader in the 2025 SPARK Matrix™ for In-App Protection by QKS Group. Verimatrix has been recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™. The compan
Amazon to Invest More Than $4 Billion to Launch Infrastructure Region in Chile7.5.2025 15:00:00 CEST | Press release
New AWS South America (Chile) Region will enable customers to run workloads and securely store their content in Chile while serving end users with even lower latencyActive customers in Chile include AgroSuper, Andres Bello University, Banco de Chile, Banco Itaú, BancoEstado, BCI Mach, Cencosud, Coca-Cola Andina, Coopeuch, Copec, Data Observatory, Femsa Salud, LATAM Airlines, Salcobrand, Transbank, and many others innovating on AWS Amazon (NASDAQ: AMZN) today announced it plans to launch an Amazon Web Services (AWS) infrastructure Region in Chile by the end of 2026. The new AWS South America (Chile) Region will give developers, startups, entrepreneurs, and enterprises, as well as financial services, retail, education, government, and nonprofit organizations, greater choice for running their applications and serving end users from data centers located in Chile. As part of its long-term commitment, Amazon is planning to invest more than $4 billion in Chile to support the construction, con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom